 Various progestins have been investigated including Megace megesterol acetate and Provera medroxyprogesterone acetate for the treatment of endometrial cancer. These agents are generally well tolerated and have been reported to have response rates of 15-30 with long-term complete responses not uncommonly experienced. Furthermore, median survival in patients treated with progestins ranges from 9 to 20 months. 